Retevmo FDA approval : Eli Lilly and Company (Lilly) has secured approval from the US Food and Drug Administration (FDA) for Retevmo (selpercatinib, 40mg and 80mg capsules) for the treatment of adults with metastatic rearranged during transfection (RET) fusion-positive non-small cell lung cancer (NSCLC). Retevmo has also been approved by the FDA for the treatment […]
Eli Lilly and Company, the US-based pharmaceutical giant, has finalised its $8 billion acquisition of Connecticut-based biopharmaceutical firm Loxo Oncology, a move expected to significantly enhance its oncology portfolio. The deal, initially announced in January 2019, marks a pivotal step in Lilly’s strategy to focus on precision medicines tailored for cancers driven by specific gene […]
Eli Lilly and Company (Lilly), a global leader in pharmaceuticals, has made headlines with its announcement to acquire Loxo Oncology, a pioneering biopharmaceutical company based in Stamford, Connecticut. The all-cash deal, valued at $8 billion, is poised to significantly enhance Lilly’s oncology portfolio by integrating Loxo Oncology’s cutting-edge precision medicines. A strategic move in oncology […]